Articles
| Open Access |
https://doi.org/10.55640/
INDICATORS OF CARDIOVASCULAR DEFECTS AND DISEASES AFTER CORONAVIRUS. NEW METHODS AND INDICATIONS FOR THE TREATMENT OF HEART FAILURE AND HEART FAILURE.
Fatullayev Hikmatxuja Jasur ugli,Zikirova Dilobar Fatulloyevna,Mukhammedova Sevara Nigmatulla kizi , Student of group 208 of the 2nd Faculty of Pediatrics, Medical Biology and Fundamental Medicine of TSMU,Biology teacher of the 2nd category at the 5th general secondary school of Shofirkan district, Bukhara region,Assistant Professor, PhD, Department of Medical Informatics and Biophysics, Medical Biology, Medical and Biological Chemistry, TSMUAbstract
COVID-19 infection seriously damages not only the respiratory system, but also the cardiovascular system. This article discusses post-coronavirus cardiac pathologies, their mechanisms of origin, statistical indicators, as well as modern approaches and new treatment methods in the treatment of heart failure, cardiovascular diseases and heart failure.
Keywords
COVID-19, heart failure, heart failure, post-COVID syndrome, heart defects, TAVI, myocarditis, cardiology, long COVID, ECG and Holter monitoring, Echocardiography (UZI).
References
Gupta A., Madhavan M.V., Sehgal K., et al. Extrapulmonary manifestations of COVID-19. Nature Medicine. 2020;26(7):1017–1032.
Shi S., Qin M., Shen B., et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19. JAMA Cardiology. 2020;5(7):802–810.
Clerkin K.J., Fried J.A., Raikhelkar J., et al. COVID-19 and cardiovascular disease. Circulation. 2020;141(20):1648–1655.
Xie Y., Xu E., Bowe B., Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nature Medicine. 2022;28:583–590.
European Society of Cardiology (ESC). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021.
ACC/AHA/HFSA. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022.
Otto C.M., Nishimura R.A., Bonow R.O., et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021.
Tersalvi G., Vicenzi M., Calabretta D., et al. Elevated troponin in patients with coronavirus disease 2019.
Journal of Cardiac Failure. 2020;26(6):470–475.
ESC Working Group on Cardiovascular Pharmacotherapy. Cardiovascular sequelae of COVID-19. European Heart Journal. 2023.
World Health Organization (WHO). Clinical management of COVID-19: living guidance. 2023.
Zheng, Y. Y., et al. (2020). "COVID-19 and the cardiovascular system." Nature Reviews Cardiology.
Guagliumi, G., et al. (2021). "Endothelial Cell Infection and Endotheliitis in COVID-19." The Lancet.
Xie, Y., et al. (2022). "Long-term cardiovascular outcomes of COVID-19." Nature Medicine.
Al-Aly, Z., et al. (2021). "Long COVID after breakthrough SARS-CoV-2 infection." Nature Medicine.
Ayoubkhani, D., et al. (2023). "Risk of Long COVID in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort study." BMJ.
Mack, M. J., et al. (2021). "Transcatheter Aortic-Valve Replacement in Low-Risk Patients." The New England Journal of Medicine (PARTNER 3 trial).
Stone, G. W., et al. (2018). "Transcatheter Mitral-Valve Repair in Patients with Heart Failure." The New England Journal of Medicine (COAPT trial).
McMurray, J. J. V., et al. (2014). "Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure." The New England Journal of Medicine (PARADIGM-HF trial).
Packer, M., et al. (2020). "Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure." The New England Journal of Medicine (EMPEROR-Reduced trial).
Article Statistics
Downloads
Copyright License
This work is licensed under a Creative Commons Attribution 4.0 International License.